Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064996 | 0.98 | TSHR (0.57) | TSHRALDH1A1EPHX1CHRNB2CHRNA7 | |
| SCHEMBL11488583 | 0.85 | TSHR (0.64) | TSHRALDH1A1EPHX1ALOX5 | |
| SCHEMBL29385123 | 0.84 | EPHX1 (0.48) | TSHRALDH1A1EPHX1CHRNB2CHRNA7 | |
| SCHEMBL28380195 | 0.84 | EPHX1 (0.48) | TSHRALDH1A1EPHX1CHRNB2CHRNA7 | |
| SCHEMBL29559353 | 0.84 | EPHX1 (0.48) | TSHRALDH1A1EPHX1CHRNB2CHRNA7 | |
| SCHEMBL28249807 | 0.84 | EPHX1 (0.48) | TSHRALDH1A1EPHX1CHRNB2CHRNA7 | |
| SCHEMBL11371393 | 0.82 | TSHR (0.37) | TSHRALOX5 | |
| SCHEMBL8791144 | 0.82 | EPHX1 (0.44) | TSHRALDH1A1EPHX1CHRNB2CHRNA7 | |
| SCHEMBL679389 | 0.81 | TSHR (0.59) | TSHRALDH1A1EPHX1ALOX5S1PR2 | |
| SCHEMBL29396884 | 0.81 | EPHX1 (0.37) | TSHRALDH1A1EPHX1CHRNB2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622874-B2 | Trans-crocetin compositions and treatment regimens | L.E.A.F. HOLDINGS GROUP LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260014079-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4667017-A2 | CAROTENOID COMPOSITIONS AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3787607-B1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367121-A1 | DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTS | AXSOME THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12458597-B2 | Carotenoid compositions and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230210803-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | L E A F HOLDINGS GROUP LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20220409565-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458597-B2 | Carotenoid compositions and uses thereof | STARD7, LRAT, HCCS | TSHR 4232/4885ALDH1A1 3260/4885EPHX1 961/4885 |
| US-12622874-B2 | Trans-crocetin compositions and treatment regimens | CPT2, SOD1, TFRC | TSHR 3189/4885ALDH1A1 3466/4885EPHX1 3804/4885 |
| US-20220409565-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | STARD7, LRAT, HCCS | TSHR 4232/4885ALDH1A1 3260/4885EPHX1 961/4885 |
| US-20230210803-A1 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | TTPA, HIF1A, HIF1AN | TSHR 3858/4885ALDH1A1 1939/4885EPHX1 2119/4885 |
| US-20260014079-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | STARD7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPT2 | TSHR 3548/4885ALDH1A1 4215/4885EPHX1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.